Stroke Product Under Development

Menlo Park, CA, December 22, 2000.  LifeSense, LLC, a Menlo Park start-up company, is developing a potentially life-saving, stroke-related product, invented by Robert Bornn.   Says Bornn, founder and president, “we want stroke victims to be able to take advantage of recent medical advances in the area of stroke care.  If a stroke victim gets the right medical attention in the first 3-4 hours after a stroke, there are new clot-busting drugs that can reduce stroke damage.  Our low-cost, proprietary product would help people get the medical attention they need in time to make a big difference in their quality of life after a stroke.”

Mr. Bornn believes that this product will be used by individuals who, without it, would be at risk of delayed detection of stroke.  This includes stroke survivors of all ages.  It also includes the increasing number of elders living at home, especially those living alone, or 10 million people in 1990 (Bureau of the Census, 1990 and Bureau of Commerce, 1990).  Says Bornn, “many stroke survivors and their families will find greater peace of mind with our product because the incidence of a repeat “brain attack” increases about 10% or more every year after a stroke.” 

Bornn continues, “This is a good product for society.  Every year stroke costs us about $30 billion.”  He continues, “This is also a good product for our ailing health care system.  Not only patients, but also physicians, hospitals, and insurance companies will benefit.  Physicians will appreciate seeing their patients receiving timely intervention.  Because stroke survivors are likely to be admitted during and following hospital-based definitive drug treatment, our product could be a factor in modestly improving hospital patient census.  Health insurers are likely to see an overall decreasing cost associated with managing the extent of injury from stroke as well as shorter rehabilitation." 

Says Mr. Bornn, “I’m pleased that we have been able to put together an exceptionally seasoned and sophisticated, multi-disciplinary team to develop our product.  We are working with high-level stroke specialists and neurologists from Stanford, as well as well-regarded engineers and researchers, to commercialize the product.”  During the past twenty-five years, Bornn has contributed technology to four other R&D companies of which he has also been founder and President.  He has patents in related areas, five of which are granted, with others pending. 

Every minute one person (U.S.) suffers a debilitating stroke or a fall which may result in paralysis or unconsciousness.  Many are alone or undetected and do not receive timely care.  Stroke is the third leading cause of death in the U.S. with nearly 160,000 lost each year.  During each lifetime, four of five families (U.S.) will be affected by stroke.  Each year more than 730,000 suffer from stroke and an estimated 570,000 new stroke survivors suffer a diminished quality of life because their strokes are not detected and treatment initiated in time to make a difference.  Approximately one in five of these people will experience another stroke within a year. This figure rises to more than one in three cumulatively within 3 years.  There are currently more than 3 million stroke survivors (U.S.)  (http://www.stroke.org/brain_stat.cfm).  50 million people (U.S.) have been estimated to be at high risk of stroke and other cerebrovascular problems (National Center for Health Statistics).

For investment and other information, please contact Robert Bornn, President, LifeSense, LLC, at (650) 368-1946 or robert@bornn.com.